4,901 trials
Airway Extubation
Primary: Evaluate Feasibility of Enrolling and Consenting Greater Than 50% of Eligible Patients — 30 Participants
Cerebral Palsy
Primary: Changes in C-reactive Protein (hsCRP) — 2.32; 2.66 mg/L
HIV-1-infection
Primary: Substudies 01, 02 and 03: Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical…
Healthy
Primary: Mean Protein O-GlcNAcylation in Peripheral Blood Mononuclear Cells (PBMCs) — 100.0; 100.0; 219.33; 232.79 percentage of protein O-GlcNAcylation
Healthy Participants
Primary: Regional Total Volume of Distribution (VT) of [18F]-IMA601 in Frontal Lobe at Each Brain Scan — 14.09; 1.82; 4.76; 16.08 milliliters/cubic centimeter (mL/cm^3)
Healthy Volunteer Study
Primary: Change From Baseline in Observer's Assessment of Alertness/Sedation Scale (OAAS/S) (Part A) — 0; 0; 0; 0 score on a scale (change)
GERD
Primary: AUC0-24h Linaprazan (QD) — 5057; 8924; 13900; 4640 nmol/L*h
Healthy
Primary: Area Under the Concentration-Time Curve From Time Zero to The Time of The Last Quantifiable Concentration (AUClast) of Sisunatovir PIC Versus (vs) WGT in a Fasted State…
Obesity · Healthy
Primary: Glucagon-Like Peptide-1 (GLP-1) — 18; 17 Participants
Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) of Venetoclax When Administered With Gemtuzumab Ozogamicin (GO) — 600 mg
Osteo Arthritis Knee
Primary: Change in Sleep Disturbance as Measured by Epworth Sleep Score (ESS) — 7.2; 6.2; 6; 6.8 score on a scale
Relapsed or Refractory Classical Hodgkin Lymphoma
Primary: Part A (Dose Escalation): Number of Participants With Adverse Events (AEs) — 1; 1; 1; 1 Participants
Healthy Participants
Primary: Evaluation of the Bioequivalent Rate of Absorption (Cmax) of Riluzole After Replicate Single Dose Administration of Test and Reference — 315.62; 278.81 ng/mL — p=<0.0001
Lung Adenocarcinoma · Ovarian Cancer · Peritoneal Carcinoma
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03 — 3; 3; 2; 0 Participants
Chronic Obstructive Pulmonary Disease
Primary: Area Under Plasma Concentration-time Curve From Zero to Infinity (AUCinf) — 4047; 4112; 4012; 85.62 hour*picogram/milliliter (h*pg/mL)